Meng-Xin Tian

List of Publications by Year
in descending order

32 papers	962 citations	567281 15 h-index	477307 29 g-index
32 all docs	32 docs citations	32 times ranked	1820 citing authors

#	Article	IF	Citations
1	Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack. Hepatology, 2023, 77, 109-123.	7.3	31
2	A New Scoring Method for Personalized Prognostic Prediction in Patients with Combined Hepatocellular and Cholangiocarcinoma After Surgery. Journal of Gastrointestinal Surgery, 2021, 25, 971-982.	1.7	5
3	Cystathionine Î²-synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis. , 2021, 9, e003031.		33
4	P-L12â€ƒExploring Pathological Signatures for Predicting Recurrence of Early-stage Hepatocellular Carcinoma Based on Deep Learning. British Journal of Surgery, 2021, 108, .	0.3	0
5	Adjuvant Transarterial chemoembolization does not influence recurrence-free or overall survival in patients with combined hepatocellular carcinoma and Cholangiocarcinoma after curative resection: a propensity score matching analysis. BMC Cancer, 2020, 20, 642.	2.6	9
6	Albumin-to-Alkaline Phosphatase Ratio is an Independent Prognostic Indicator in Combined Hepatocellular and Cholangiocarcinoma. Journal of Cancer, 2020, 11, 5177-5186.	2.5	14
7	Heterogeneity of exhausted T cells in the tumor microenvironment is linked to patient survival following resection in hepatocellular carcinoma. OncoImmunology, 2020, 9, 1746573.	4.6	21
8	Nine-factor-based immunohistochemistry classifier predicts recurrence for early-stage hepatocellular carcinoma after curative resection. British Journal of Cancer, 2020, 123, 92-100.	6.4	10
9	Age-adjusted Charlson Comorbidity Index predicts survival in intrahepatic cholangiocarcinoma patients after curative resection. Annals of Translational Medicine, 2020, 8, 487-487.	1.7	25
10	Identification of FABP5 as an immunometabolic marker in human hepatocellular carcinoma. , 2020, 8, e000501.		29
11	Prediction of overall survival in resectable intrahepatic cholangiocarcinoma: IS ICC â€applied prediction model. Cancer Science, 2020, 111, 1084-1092.	3.9	14
12	Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy. Cancer Immunology, Immunotherapy, 2019, 68, 1369-1378.	4.2	12
13	Prognostic Value and Predication Model of Microvascular Invasion in Patients with Intrahepatic Cholangiocarcinoma. Journal of Cancer, 2019, 10, 5575-5584.	2.5	28
14	Development and validation of a prognostic score predicting recurrence in resected combined hepatocellular cholangiocarcinoma . Cancer Management and Research, 2019, Volume 11, 5187-5195.	1.9	12
15	Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma. BMC Medicine, 2019, 17, 106.	5.5	31
16	Immunotherapy of hepatocellular carcinoma: strategies for combinatorial intervention. Science China Life Sciences, 2019, 62, 1138-1143.	4.9	19
17	Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment. Neoplasia, 2019, 21, 1133-1142.	5.3	44
18	Daily decrease of post-operative alpha-fetoprotein by 9% discriminates prognosis of HCC: A multicenter retrospective study. Aging, 2019, 11, 11111-11123.	3.1	6

#	Article	IF	Citations
19	<scp>SIRT</scp> 5 inhibits peroxisomal <scp>ACOX</scp> 1 to prevent oxidative damage and is downregulated in liver cancer. EMBO Reports, 2018, 19, .	4.5	171
20	A Novel Risk prediction Model for Patients with Combined Hepatocellular-Cholangiocarcinoma. Journal of Cancer, 2018, 9, 1025-1032.	2.5	14
21	Autophagy activation contributes to glutathione transferase Mu 1â€‘mediated chemoresistance in hepatocellular carcinoma. Oncology Letters, 2018, 16, 346-352.	1.8	12
22	Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger Patients: A Propensity Score Matching Analysis. Journal of Cancer, 2018, 9, 1106-1112.	2.5	16
23	Perioperative blood transfusion does not affect recurrence-free and overall survivals after curative resection for intrahepatic cholangiocarcinoma: a propensity score matching analysis. BMC Cancer, 2017, 17, 762.	2.6	12
24	Coagulopathy associated with poor prognosis in intrahepatic cholangiocarcinoma patients after curative resection. BioScience Trends, 2017, 11, 469-474.	3.4	3
25	CCL24 contributes to HCC malignancy via RhoB- VEGFA-VEGFR2 angiogenesis pathway and indicates poor prognosis. Oncotarget, 2017, 8, 5135-5148.	1.8	35
26	Destabilization of Fatty Acid Synthase by Acetylation Inhibits De Novo Lipogenesis and Tumor Cell Growth. Cancer Research, 2016, 76, 6924-6936.	0.9	92
27	Lamp2a is required for tumor growth and promotes tumor recurrence of hepatocellular carcinoma. International Journal of Oncology, 2016, 49, 2367-2376.	3.3	39
28	The SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to be mined. World Journal of Surgical Oncology, 2016, 14, 131.	1.9	25
29	Caveolin-1 promotes tumor growth and metastasis via autophagy inhibition in hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 169-178.	1.5	32
30	The nanomechanical signature of liver cancer tissues and its molecular origin. Nanoscale, 2015, 7, 12998-13010.	5.6	75
31	PKM2 promotes metastasis by recruiting myeloid-derived suppressor cells and indicates poor prognosis for hepatocellular carcinoma. Oncotarget, 2015, 6, 846-861.	1.8	84
32	LOXL4 is downregulated in hepatocellular carcinoma with a favorable prognosis. International Journal of Clinical and Experimental Pathology, 2015, 8, 3892-900.	0.5	9